Report Summary



"IBD- Market Insights, Epidemiology and Market Forecast 2028" report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2016-2028.



Market Segment by Countries, coveringï¼š

United States

EU5 Germany, France, Italy, Spain and the United Kingdom

Japan



Study Period: 2016-2028



IBD Understanding and Treatment Algorithm

The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for IBDin the US, Europe, and Japan are also provided in the report.



IBD Epidemiology

This section provide the insights about historical and current patient pool and forecasted trend for 7 jor markets. It takes in to account the analysis of numerous studies, survey reports as well as KOLâ€™s views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.



IBD Product Profiles & Analysis

This part of the IBD report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.



IBD Market Outlook

The IBD market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barrie and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteriaâ€™s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders . The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.



IBD Market Share by Therapies

This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new ugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.



IBD Report Insights

Patient Population in IBD

Therapeutic Approaches in IBD

IBD Pipeline Analysis

IBD Market Size and Trends

IBD Market Opportunities

Impact of upcoming Therapies in IBD



IBD Report Key Strengths

10 Year Forecast

7MM Coverage

Epidemiology Segmentation

Drugs Uptake

Highly Analyzed Market

Key Cross Competition



IBD Report Assessment

Current Treatment Practices in IBD

Unmet Needs in IBD

Detailed IBD Pipeline Product Profiles

Market Attractiveness

Market Drivers and Barriers



Key Benefits



This report will help to develop Business Strategies by understanding the trends shaping and driving the IBD market

Organize sales and marketing efforts by identifying the best opportunities for IBD market

To understand the future market competition in the IBD market.



Note: We understand the needs of the rapidly changing market and is helping the client by providing the most up to date Report. It usually takes 4-5 days to deliver this kind of Report. The report coverage will depend on the availability of the data.

Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

1 Key Insights

2 IBD Market Overview at a Glance

2.1 Market Share % Distribution of IBD in 2018

2.2 Market Share % Distribution of IBD in 2028

3 IBD: Disease Background and Overview

3.1 Introduction

3.2 Symptoms

3.3 Etiology

3.4 Risk Factor

3.5 Pathophysiology

3.6 Diagnosis

3.7 Treatment

4 Epidemiology and Patient Population

4.1. Key Findings

4.2. Total Prevalent/ Incident Patient Population of IBD in 7MM

4.3. Total Prevalent Patient Population of IBD in 7MM â€“ By Countries

5 Epidemiology of IBD by Countries 2016-2028

5.1 United States- Epidemiology 2016-2028

5.1.1 Assumptions and Rationale

5.1.2 Prevalent/Incident Cases of IBD in the United States

5.1.3 Sub-Type Specific cases of IBD in the United States

5.1.4 Sex- Specific Cases of IBD in the United States

5.1.5 Diagnosed Cases of IBD in the United States

5.1.6 Treatable Cases of IBD in the United States

5.2 EU5 Countries

5.2.1 Germany

5.2.1.1 Assumptions and Rationale

5.2.1.2 Prevalent/Incident Cases of the of IBD in the Germany

5.2.1.3 Sub-Type Specific cases of IBD in the Germany

5.2.1.4 Sex- Specific Cases of the IBD in the Germany

5.2.1.5 Diagnosed Cases of the IBD in the Germany

5.2.1.6 Treatable Cases of the IBD

5.2.2 France

5.2.2.1 Assumptions and Rationale

5.2.2.2 Prevalent/Incident Cases of the of IBD in the France

5.2.2.3 Sub-Type Specific cases of IBD in the France

5.2.2.4 Sex- Specific Cases of the IBD in the France

5.2.2.5 Diagnosed Cases of the IBD in the France

5.2.2.6 Treatable Cases of the IBD

5.2.3 Italy

5.2.3.1 Assumptions and Rationale

5.2.3.2 Prevalent/Incident Cases of the of IBD in the Italy

5.2.3.3 Sub-Type Specific cases of IBD in the Italy

5.2.3.4 Sex- Specific Cases of the IBD in the Italy

5.2.3.5 Diagnosed Cases of the IBD in the Italy

5.2.3.6 Treatable Cases of the IBD

5.2.4 Spain

5.2.4.1 Assumptions and Rationale

5.2.4.2 Prevalent/Incident Cases of the of IBD in the Spain

5.2.4.3 Sub-Type Specific cases of IBD in the Spain

5.2.4.4 Sex- Specific Cases of the IBD in the Spain

5.2.4.5 Diagnosed Cases of the IBD in the Spain

5.2.4.6 Treatable Cases of the IBD

5.2.5 United Kingdom

5.2.5.1 Assumptions and Rationale

5.2.5.2 Prevalent/Incident Cases of the of IBD in the United Kingdom

5.2.5.3 Sub-Type Specific cases of IBD in the United Kingdom

5.2.5.4 Sex- Specific Cases of the IBD in the United Kingdom

5.2.5.5 Diagnosed Cases of the IBD in the United Kingdom

5.2.5.6 Treatable Cases of the IBD

5.3 Japan

5.3.1 Assumptions and Rationale

5.3.2 Prevalent/Incident Cases of the of IBD in the Japan

5.3.3 Sub-Type Specific cases of IBD in the Japan

5.3.4 Sex- Specific Cases of the IBD in the Japan

5.3.5 Diagnosed Cases of the IBD in the Japan

5.3.6 Treatable Cases of the IBD

6 Current Treatment & Medical practices

6.1 Treatment Algorithm

6.2 Treatment Guidelines

7 Unmet Needs

8 Marketed Product

8.1 Drug A: Company 1

8.1.1 Drug Description

8.1.2 Mechanism of Action

8.1.3 Clinical Trials Details

8.1.4 Advantages & Disadvantages

8.1.5 Safety and Efficacy

8.1.6 Product Profile

8.2 Drug B: Company 2

8.2.1 Drug Description

8.2.2 Mechanism of Action

8.2.3 Clinical Trials Details

8.2.4 Advantages & Disadvantages

8.2.5 Safety and Efficacy

8.2.6 Product Profile

8.3 Drug C: Company 3

8.3.1 Drug Description

8.3.2 Mechanism of Action

8.3.3 Clinical Trials Details

8.3.4 Advantages & Disadvantages

8.3.5 Safety and Efficacy

8.3.6 Product Profile

8.4 Drug D: Company 4

8.4.1 Drug Description

8.4.2 Mechanism of Action

8.4.3 Clinical Trials Details

8.4.4 Advantages & Disadvantages

8.4.5 Safety and Efficacy

8.4.6 Product Profile

8.5 Drug E: Company 5

8.5.1 Drug Description

8.5.2 Mechanism of Action

8.5.3 Clinical Trials Details

8.5.4 Advantages & Disadvantages

8.5.5 Safety and Efficacy

8.5.6 Product Profile

8.6 : Company 6

8.6.1 Drug Description

8.6.2 Mechanism of Action

8.6.3 Clinical Trials Details

8.6.4 Advantages & Disadvantages

8.6.5 Safety and Efficacy

8.6.6 Product Profile

8.7 : Company 7

8.7.1 Drug Description

8.7.2 Mechanism of Action

8.7.3 Clinical Trials Details

8.7.4 Advantages & Disadvantages

8.7.5 Safety and Efficacy

8.7.6 Product Profile

8.8 : Company 8

8.8.1 Drug Description

8.8.2 Mechanism of Action

8.8.3 Clinical Trials Details

8.8.4 Advantages & Disadvantages

8.8.5 Safety and Efficacy

8.8.6 Product Profile

9 Emerging Drugs

9.1 Key Cross Competition

9.2 Emerging company

9.2.1 Emerging Drug A: Company 12

9.2.1.1 Other Development Activities

9.2.1.2 Clinical Development

9.2.1.3 Clinical Trials Information

9.2.1.4 Safety and Efficacy

9.2.1.5 Advantages and Disadvantages

9.2.1.6 Product Profile

9.2.2 Emerging Drug B: Company 13

9.2.2.1 Other Development Activities

9.2.2.2 Clinical Development

9.2.2.3 Clinical Trials Information

9.2.2.4 Safety and Efficacy

9.2.2.5 Advantages and Disadvantages

9.2.2.6 Product Profile

9.2.3 Emerging Drug C: Company 14

9.2.3.1 Other Development Activities

9.2.3.2 Clinical Development

9.2.3.3 Clinical Trials Information

9.2.3.4 Safety and Efficacy

9.2.3.5 Advantages and Disadvantages

9.2.3.6 Product Profile

9.2.4 Emerging Drug D: Company 15

9.2.4.1 Other Development Activities

9.2.4.2 Clinical Development

9.2.4.3 Clinical Trials Information

9.2.4.4 Safety and Efficacy

9.2.4.5 Advantages and Disadvantages

9.2.4.6 Product Profile

9.2.5 Emerging Drug E: Company 16

9.2.5.1 Other Development Activities

9.2.5.2 Clinical Development

9.2.5.3 Clinical Trials Information

9.2.5.4 Safety and Efficacy

9.2.5.5 Advantages and Disadvantages

9.2.5.6 Product Profile

10 7MM Market Analysis

10.1 7MM Market Size of IBD

10.2 7MM Percentage Share of Drugs Marketed for IBD

10.3 7MM Market Sales of IBD by Products

11 The United States Market Outlook

11.1 Market Size of IBD in United States

11.2 Percentage Share of Drugs Marketed for IBD in United States

11.3 Market Sales of IBD by Products in United States

11.4 Analysis of Upcoming Therapies and Impact on the Market

12 EU5 Countries Market Outlook

12.1 Market Size of IBD in EU5

12.2 Market Size of IBD in Germany

12.2.1 Market Size of IBD in Germany

12.2.2 Percentage Share of Drugs Marketed for IBD in Germany

12.2.3 Market Sales of IBD by Products in Germany

12.2.4 Analysis of Upcoming Therapies and Impact on the Market

12.3 Market Size of IBD in France

12.3.1 Market Size of IBD in France

12.3.2 Percentage Share of Drugs Marketed for IBD in France

12.3.3 Market Sales of IBD by Products in France

12.3.4 Analysis of Upcoming Therapies and Impact on the Market

12.4 Market Size of IBD in Italy

12.4.1 Market Size of IBD in Italy

12.4.2 Percentage Share of Drugs Marketed for IBD in Italy

12.4.3 Market Sales of IBD by Products in Italy

12.4.4 Analysis of Upcoming Therapies and Impact on the Market

12.5 Market Size of IBD in Spain

12.5.1 Market Size of IBD in Spain

12.5.2 Percentage Share of Drugs Marketed for IBD in Spain

12.5.3 Market Sales of IBD by Products in Spain

12.5.4 Analysis of Upcoming Therapies and Impact on the Market

12.6 Market Size of IBD in United Kingdom

12.6.1 Market Size of IBD in United Kingdom

12.6.2 Percentage Share of Drugs Marketed for IBD in United Kingdom

12.6.3 Market Sales of IBD by Products in United Kingdom

12.6.4 Analysis of Upcoming Therapies and Impact on the Market

13 The Japan Market Outlook

13.1 Market Size of IBD in Japan

13.2 Percentage Share of Drugs Marketed for IBD in Japan

13.3 Market Sales of IBD by Products in Japan

13.4 Analysis of Upcoming Therapies and Impact on the Market

14 Cost Analysis of IBD

15 Generic Competition in IBD Market

16 Market Drivers

17 Market Barriers

18 Report Methodology

18.1 Methodology/Research Approach

18.2 Data Source

18.2.1 Secondary Sources

18.2.2 Primary Sources

List of Tables

Table Total Prevalent/Incident Cases of the IBD in 7MM 2016-2028

Table Total Prevalent/Incident Cases of the IBD in 7MM by Countries 2016-2028

Table Prevalent/Incident Cases of the IBD in United States 2016-2028

Table Sub-Type Specific cases of IBD in the United States 2016-2028

Table Sex- Specific Cases of IBD in the United States 2016-2028

Table Diagnosed Cases of the IBD in United States 2016-2028

Table Treatable Cases of the IBD in United States 2016-2028

Table Prevalent/Incident Cases of the IBD in Germany 2016-2028

Table Sub-Type Specific cases of IBD in the Germany 2016-2028

Table Sex- Specific Cases of IBD in the Germany 2016-2028

Table Diagnosed Cases of the IBD in Germany 2016-2028

Table Treatable Cases of the IBD in Germany 2016-2028

Table Prevalent/Incident Cases of the IBD in France 2016-2028

Table Sub-Type Specific cases of IBD in the France 2016-2028

Table Sex- Specific Cases of IBD in the France 2016-2028

Table Diagnosed Cases of the IBD in France 2016-2028

Table Treatable Cases of the IBD in France 2016-2028

Table Prevalent/Incident Cases of the IBD in Italy 2016-2028

Table Sub-Type Specific cases of IBD in the Italy 2016-2028

Table Sex- Specific Cases of IBD in the Italy 2016-2028

Table Diagnosed Cases of the IBD in Italy 2016-2028

Table Treatable Cases of the IBD in Italy 2016-2028

Table Prevalent/Incident Cases of the IBD in Spain 2016-2028

Table Sub-Type Specific cases of IBD in the Spain 2016-2028

Table Sex- Specific Cases of IBD in the Spain 2016-2028

Table Diagnosed Cases of the IBD in Spain 2016-2028

Table Treatable Cases of the IBD in Spain 2016-2028

Table Prevalent/Incident Cases of the IBD in United Kingdom 2016-2028

Table Sub-Type Specific cases of IBD in the United Kingdom 2016-2028

Table Sex- Specific Cases of IBD in the United Kingdom 2016-2028

Table Diagnosed Cases of the IBD in United Kingdom 2016-2028

Table Treatable Cases of the IBD in United Kingdom 2016-2028

Table Prevalent/Incident Cases of the IBD in Japan 2016-2028

Table Sub-Type Specific cases of IBD in the Japan 2016-2028

Table Sex- Specific Cases of IBD in the Japan 2016-2028

Table Diagnosed Cases of the IBD in Japan 2016-2028

Table Treatable Cases of the IBD in Japan 2016-2028

Table Drug Description

Table Mechanism of Action

Table Clinical Trials Details

Table Advantages & Disadvantages

Table Safety and Efficacy

Table Product Profile

Table Drug Description

Table Mechanism of Action

Table Clinical Trials Details

Table Advantages & Disadvantages

Table Safety and Efficacy

Table Product Profile

Table Drug Description

Table Mechanism of Action

Table Clinical Trials Details

Table Advantages & Disadvantages

Table Safety and Efficacy

Table Product Profile

Table Drug Description

Table Mechanism of Action

Table Clinical Trials Details

Table Advantages & Disadvantages

Table Safety and Efficacy

Table Product Profile

Table Drug Description

Table Mechanism of Action

Table Clinical Trials Details

Table Advantages & Disadvantages

Table Safety and Efficacy

Table Product Profile

Table Drug Description

Table Mechanism of Action

Table Clinical Trials Details

Table Advantages & Disadvantages

Table Safety and Efficacy

Table Product Profile

Table Drug Description

Table Mechanism of Action

Table Clinical Trials Details

Table Advantages & Disadvantages

Table Safety and Efficacy

Table Product Profile

Table Drug Description

Table Mechanism of Action

Table Clinical Trials Details

Table Advantages & Disadvantages

Table Safety and Efficacy

Table Product Profile

Table Comparison of emerging drugs Immunomodulators under development

Table Comparison of emerging drugs other classes under development

Table Safety and Efficacy

Table Product Advantages and Advantages

Table Clinical Trial Description, 2018

Table Safety and Efficacy

Table Product Advantages and Advantages

Table Clinical Trial Description, 2018

Table Safety and Efficacy

Table Product Advantages and Advantages

Table Clinical Trial Description, 2018

Table Safety and Efficacy

Table Product Advantages and Advantages

Table Clinical Trial Description, 2018

Table Safety and Efficacy

Table Product Advantages and Advantages

Table Clinical Trial Description, 2018

Table7MM- Market Size of IBD in USD MM 2016-2028

Table 7MM- Market Share IBD by Therapies in USD MM 2016-2028

Table 7MM- Market Sales of IBD by Therapies in USD MM 2016-2028

Table US Market Size of IBD in USD, Million 2016-2028

Table United States-Market Share IBD by Therapies in USD MM 2016-2028

Table United States-Market Sales of IBD by Therapies in USD MM 2016-2028

Table EU5 Market Size of IBD MS in USD, Million 2016-2028

Table Germany Market Size of IBD in USD, Million 2016-2028

Table Germany -Market Share IBD by Therapies in USD MM 2016-2028

Table Germany -Market Sales of IBD by Therapies in USD MM 2016-2028

Table France Market Size of IBD in USD, Million 2016-2028

Table France -Market Share IBD by Therapies in USD MM 2016-2028

Table France -Market Sales of IBD by Therapies in USD MM 2016-2028

Table Italy Market Size of IBD in USD, Million 2016-2028

Table Italy -Market Share IBD by Therapies in USD MM 2016-2028

Table Italy -Market Sales of IBD by Therapies in USD MM 2016-2028

Table Spain Market Size of IBD in USD, Million 2016-2028

Table Spain -Market Share IBD by Therapies in USD MM 2016-2028

Table Spain -Market Sales of IBD by Therapies in USD MM 2016-2028

Table United Kingdom Market Size of IBD in USD, Million 2016-2028

Table United Kingdom -Market Share IBD by Therapies in USD MM 2016-2028

Table United Kingdom -Market Sales of IBD by Therapies in USD MM 2016-2028

Table Japan Market Size of IBD in USD, Million 2016-2028

Table Japan -Market Share IBD by Therapies in USD MM 2016-2028

Table Japan -Market Sales of IBD by Therapies in USD MM 2016-2028

Table Market Drivers of IBD

Table Market Barriers of IBD

???